Developing cyclodextrin-based inhaled therapies for the management of infection-induced respiratory disorders.


Aquilon Pharma takes part to and coordinates a technology innovation consortium for the AEROVID project aiming at “Developing cyclodextrin-based inhaled therapies for the management of infection-induced respiratory disorders”.

Aquilon Pharma announced that the AEROVID project (duration: 30 months), launched in February 2022, was awarded a €2,3 million collaborative research grant from Belgium’s Walloon region government in coordination with the Region’s Health Competitiveness cluster BioWin.

For AEROVID, to share their know-how, Aquilon Pharma, as project coordinator, recruited fellow Wallonia-based academic partners, Université de Liège (ULiège), the CMMI «Center for Microscopy and Molecular Imaging» established on Université libre de Bruxelles (ULB) and Université de Mons (UMons), as well as the start-up Radiomics which is based in Liège and specialized in the development of Artificial Intelligence-based tools. AEROVID project partners form a world-class consortium with huge expertise in the fields of pharmacology, artificial intelligence, pneumology and inflammation. The consortium’s objectives are to improve the effectiveness of inhaled therapies and prevent the increasing prevalence of exacerbations of respiratory diseases.

“We are excited and proud to advance this promising disease management solution for the millions of people suffering from infection-induced respiratory diseases.” stated Natacha Rocks, AEROVID Project coordinator of Aquilon Pharma.

The main objectives of the AEROVID project are threefold:

For Aquilon Pharmaceuticals:

  • Development of effective inhalation therapies combining an innovative formulation technology (based on cyclodextrin and corticosteroid complexation) and last-generation pulmonary delivery devices (based on the eco-friendly Softmist technology) for the treatment of infection-induced respiratory disorders.
  • Prevention of chronic alterations induced by infection-induced respiratory diseases.

For Radiomics:

  • Development of an artificial intelligence tool that will identify lung abnormalities present in patients bearing pulmonary diseases and guide the medicine towards a personalized treatment for each care-seeking patient.

For the University Academic Units:

  • Gather an in-depth knowledge of the cellular and molecular actors at the origin of inflammation and chronic alterations in infection-induced respiratory diseases.

Follow AEROVID’s social networks to keep up with the development of the project.